Evidence map›Paper›PMID 38977346›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2024

[

Z Yang, X Zhang, X Zhang, Y Liu, J Zhang, X Yuan

Abstract readEnglish Abstract
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. New advances in oral microbiology and tumor research.World journal of clinical oncology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Z YangCollege of Clinical Medicine/First Affiliated Hospital, Henan University of Science and Technology, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Cancer Epigenetics, Luoyang 471003, China.
X ZhangCollege of Clinical Medicine/First Affiliated Hospital, Henan University of Science and Technology, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Cancer Epigenetics, Luoyang 471003, China.
X ZhangCollege of Clinical Medicine/First Affiliated Hospital, Henan University of Science and Technology, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Cancer Epigenetics, Luoyang 471003, China.
Y LiuCollege of Clinical Medicine/First Affiliated Hospital, Henan University of Science and Technology, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Cancer Epigenetics, Luoyang 471003, China.
J ZhangCollege of Clinical Medicine/First Affiliated Hospital, Henan University of Science and Technology, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Cancer Epigenetics, Luoyang 471003, China.
X YuanCollege of Clinical Medicine/First Affiliated Hospital, Henan University of Science and Technology, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Provincial Key Laboratory of Cancer Epigenetics, Luoyang 471003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effect of

methodsWe examined YTHDF2 and Fas protein expressions in esophageal squamous cell carcinoma (ESCC) tissues with and without Pg infection using immunohistochemistry and in Pg-infected KYSE150 cells using Western blotting. The interaction between YTHDF2 and Fas was investigated by co-immunoprecipitation (Co-IP). Pg-infected KYSE150 cells with lentivirus-mediated YTHDF2 knockdown were examined for changes in expression levels of YTHDF2, cathepsin B (CTSB), Fas and FasL proteins, and the effect of E64 (a cathepsin inhibitor) on these proteins were observed. After Pg infection and E64 treatment, KYSE150 cells were co-cultured with human peripheral blood mononuclear cells (PBMCs), and the expressions of T cell-related effector molecules were detected by flow cytometry.

resultsESCC tissues and cells with Pg infection showed significantly increased YTHDF2 expression and lowered Fas expression. The results of Co-IP demonstrated a direct interaction between YTHDF2 and Fas. In Pg-infected KYSE150 cells with YTHDF2 knockdown, the expression of CTSB was significantly reduced while Fas and FasL expressions were significantly increased. E64 treatment of KYSE150 cells significantly decreased the expression of CTSB without affecting YTHDF2 expression and obviously increased Fas and FasL expressions. Flow cytometry showed that in Pg-infected KYSE150 cells co-cultured with PBMCs, the expressions of Granzyme B and Ki67 were significantly decreased while PD-1 expression was significantly enhanced.

conclusionPg infection YTHDF2-dependently regulates the expression of Fas to facilitate immune escape of esophageal cancer and thus promoting cancer progression, suggesting the key role of YTHDF2 in regulating immune escape of esophageal cancer.

Indexed as

Esophageal Neoplasmsfas ReceptorPorphyromonas gingivalisRNA-Binding ProteinsBacteroidaceae InfectionsCell Line, TumorEsophageal Squamous Cell CarcinomaFas Ligand ProteinHumansTumor EscapeFas Ligand ProteinFAS protein, humanfas ReceptorRNA-Binding ProteinsYTHDF2 protein, humanesophageal squamous cell carcinomaFasm6A methylated reading protein YTHDF2Porphyromonas gingivalistumor immunity

Identifiers

PMID38977346
PMCPMC11237310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.